Abstract
US company Boston Biomedica (Boston, MA, USA) has been awarded a patent for its novel alternative to thermally cycled DNA hybridisation and amplification technology, such as PCR (Chemweb.com, 23 July). Pressure cycling technology (PCT) uses elevated hydrostatic pressure to control nucleic acid hybridisation, which, the company says, gives better control of hybridisation stringency at lower temperatures. The technology also has the potential to perform PCR under isothermal conditions by pressure cycling. MJD
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
